Incyte (INCY) Cash from Investing Activities (2010 - 2026)
Incyte (INCY) posted Cash from Investing Activities of -$88.2 million for Q1 2026, down 135.72% on a QoQ basis from -$37.4 million in Q4 2025, and down 8140.38% year-over-year from $1.1 million in Q1 2025.
Incyte (INCY) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Incyte's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$88.2 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 8140.38% year-over-year to -$88.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$191.9 million (down 182.82% YoY) and the FY2025 annual result came in at -$102.6 million, down 165.14% from the prior year.
- Cash from Investing Activities was -$88.2 million for Q1 2026 at Incyte, down from -$37.4 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $213.8 million in Q2 2024 and bottomed at -$154.5 million in Q4 2023.
- A 5-year average of -$18.8 million and a median of -$20.9 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities surged 2978.18% — and 2026, when it slumped 8140.38%.
- Incyte's Cash from Investing Activities stood at -$20.9 million in 2022, then sank by 638.81% to -$154.5 million in 2023, then jumped by 86.11% to -$21.5 million in 2024, then sank by 74.33% to -$37.4 million in 2025, then tumbled by 135.72% to -$88.2 million in 2026.
- Business Quant data shows INCY's Cash from Investing Activities at -$88.2 million in Q1 2026, -$37.4 million in Q4 2025, and -$47.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | -88.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.20 Mn |
| Mar 31, 2026 | -88.20 Mn |
| Dec 31, 2025 | -37.42 Mn |
| Dec 31, 2025 | -37.42 Mn |
| Sep 30, 2025 | -47.42 Mn |
| Sep 30, 2025 | -47.42 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | -21.47 Mn |
| Dec 31, 2024 | -21.47 Mn |
| Sep 30, 2024 | 38.27 Mn |
| Sep 30, 2024 | 38.27 Mn |
| Jun 30, 2024 | 213.82 Mn |
| Jun 30, 2024 | 213.82 Mn |
| Mar 31, 2024 | -73.11 Mn |
| Mar 31, 2024 | -73.11 Mn |
| Dec 31, 2023 | -154.50 Mn |
| Dec 31, 2023 | -154.50 Mn |